$MBIN

Merchants Bancorp price target raised to $58 from $51 at Piper Sandler

Piper Sandler has increased its price target for Merchants Bancorp (MBIN) to $58 from $51, maintaining an Overweight rating despite a mixed quarter with elevated non-accrual loans (NCOs) and slightly lower-than-expected pre-provision net revenue (PPNR). The firm expressed increased confidence after discussions with management that fraud-related issues have been mostly addressed, anticipating a meaningful reduction in credit costs and problem loan levels later in the year. The report also notes Merchants Bancorp's recent Q1 EPS of $1.25, surpassing the consensus of $1.16.

Original reporting
Published Apr 29, 2026, 9:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Apr 30, 2026, 7:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$MBIN
Bullish
medium confidence
Mentioned
$MBIN · $MBIN
Relevance
6/10
AlphAI data visualization · based on TipRanks
Decision brief

The 30-second read

$MBINBullishMed
01

Why it matters

The analyst's revised target suggests a belief that credit issues are manageable and that the bank's fundamentals are improving, which could attract investor interest.

02

Market read

The news is relevant for traders and investors focusing on regional banking stocks, especially those with recent credit challenges.

03

What to watch

Potential regulatory changes or macroeconomic shifts could adversely impact bank earnings and credit quality, offsetting positive analyst sentiment.

Relevance 6/10Timing: short to medium term (next 1-3 months)

Background

Merchants Bancorp has faced challenges with elevated non-accrual loans and mixed quarterly earnings but has recently addressed fraud-related issues, boosting confidence.

Company-level read

Ticker impact

$MBINBullishMedium confidence
Context

The news pertains directly to Merchants Bancorp, which is relevant for traders interested in banking stocks.

Expected impact

Moderate upward movement in the near to medium term, with potential for price appreciation towards the new target of $58.

Evidence & confidence

The price target increase indicates analyst confidence, supported by management discussions and improved credit outlook. However, mixed quarterly results and elevated NCOs introduce some uncertainty.

$MBINBullishMedium confidence
Context

The news is highly relevant as it directly impacts Merchants Bancorp's valuation and investor sentiment.

Expected impact

Potential for a short-term rally, with possible stabilization or correction depending on broader market conditions.

Evidence & confidence

Analyst optimism and improved credit outlook support upside, but recent NCOs and mixed earnings introduce caution.

Market effects

The banking sector may experience increased investor confidence, especially in regional banks with similar profiles.

Limited, primarily affecting investors and traders focused on the US banking sector.

Negligible, as the news pertains to a regional US bank.

Counterpoint

The increase in price target may be overly optimistic, and the recent NCOs could signal underlying credit quality issues that might limit upside.

Key entities

  • Merchants Bancorp

    A regional bank with a focus on commercial banking services.

  • Piper Sandler

    An investment bank and financial services firm providing research and advisory services.

Related articles

$MBINMed

Merchants Bancorp Reports Second Quarter of 2026 Results

Merchants Bancorp (MBIN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2621390d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 PRESS RELEASE Merchants Bancorp Reports Second Quarter of 2026 Results For Release July 28, 2026 · Net income of $78.3 million in the second quarter of 2026 increased $40.3 million, or 106%, compared to the second quarter

$MRNAHigh

MRNA Stock’s Vaccine Rally Cracks As Worst Week In 3 Months Looms — Analyst Calls It A ‘Do-Not-Trade’ Over Wild Swings

Moderna (MRNA) shares fell sharply, marking their worst week in three months. Analysts from Bernstein, TD Cowen, and BMO Capital Markets expressed mixed views on the company's cancer vaccine data, with price targets implying significant downside. Moderna reported a revenue decline in 2025 and aims for cash breakeven by 2028. Earnings are due on Nov. 6. Retail sentiment on Stocktwits remains bullish for both Moderna and Merck (MRK).

$RIOMed

Rio Tinto to invest USD1.9 billion in Kangwinan bauxite project

Rio Tinto PLC and Ltd will invest USD1.9 billion in the Kangwinan bauxite project in Queensland, Australia. The project aims to add 20 million tonnes of annual bauxite production capacity by 2032, replacing output from the Andoom mine. Construction is set to ramp up in 2027, supporting 1,300 jobs. Shares in Rio Tinto fell 2.2% to AUD147.05 in Sydney on Friday morning, according to the company and Alliance News.